Paramyxoviridae Infections - 16 Studies Found Active, not recruiting : Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2016-10-31 : Biological: RSV LID ΔM2-2 1030s vaccine Active, not recruiting : Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2016-10-25 : Biological: RSV LID cp ΔM2-2 Vaccine Recruiting : A Study to Evaluate Safety and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 17 Months : Respiratory Syncytial Virus Infections : 2016-10-06 : Biological: RSV vaccine (GSK3389245A) low dose Active, not recruiting : Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age : Respiratory Syncytial Virus Infections : 2016-08-31 : Biological: RSV LID cp ΔM2-2 Vaccine Recruiting : A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants. : Respiratory Syncytial Virus Infections : 2016-08-22 : Drug: MEDI8897 Anti-RSV monocl Active, not recruiting : RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults : Respiratory Syncytial Virus Infections : 2016-08-09 : Biological: MVA-BN-RSV MVA-mBN <<< Previous
